Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 936 trials

Hepatocellular Carcinoma: IMA970A and Durvalumab

We are testing a new treatment combination for patients with early-stage liver cancer after standard therapies. This study aims to see if it can improve treatment results.

Early Stage Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Fecal Microbiota Transplantation: KF2022#1 Trial

We are investigating how fecal microbiota transplantation may affect enzyme activities in the body. This study aims to understand its potential benefits for patients with certain health conditions.

Irritable Bowel SyndromeClostridioides difficile Infection>2 yearsSafety phase (I)GastroenterologyInternal Medicine

HER2-Positive Metastatic Breast Cancer: [177Lu]Lu-ABY-271 Treatment

We are studying a new treatment to see if it is safe and how it distributes in the body for patients with HER2-positive metastatic breast cancer. This trial will help us understand its effects on tumors and normal organs.

HER2-positive Metastatic Breast Cancer3-6 monthsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Recurrent Solid Cancer: PEP-010 Treatment Study

We are testing a new peptide drug, PEP-010, for patients with recurrent or metastatic solid cancers. The study will evaluate its safety and how well it works alone and with other chemotherapy drugs.

Recurrent and Metastatic Solid CancerSafety phase (I)Oncology

Procizumab for Critical Cardiovascular Care

We are evaluating a new treatment for patients receiving critical care for cardiovascular issues. This study aims to understand its safety and potential benefits in this high-risk group.

Cardiogenic Shock>2 yearsSafety phase (I)CardiologyInternal Medicine

Blood Cancers: Trichostatin A Dose Study

We are exploring the highest safe dose of Trichostatin A for individuals with relapsed or refractory blood cancers. This study aims to ensure the treatment can be tolerated by patients.

Relapsed/Refractory Blood CancersSafety phase (I)HematologyOncology

Drug Interaction Study: Itraconazole and AZD5004

We are investigating how multiple doses of itraconazole affect the movement of AZD5004 in healthy adults. Additionally, we’re looking at how AZD5004 influences the movement of hormones in healthy women.

Healthy Participants6-12 monthsSafety phase (I)Gynecology and ObstetricsInternal Medicine

Type 2 Diabetes: Retatrutide Study

We are evaluating how Retatrutide affects insulin secretion and sensitivity in adults with type 2 diabetes. This research may help improve diabetes management.

Diabetes Mellitus1-2 yearsSafety phase (I)EndocrinologyInternal Medicine

Type 2 Diabetes: Once-Weekly Retatrutide

We are investigating how well once-weekly Retatrutide works for people with type 2 diabetes and its effects on blood sugar levels. This study aims to understand the risk of hypoglycemia in participants.

Type 2 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

Skin Inflammation and Antibiotic Effectiveness Study

We are examining how medications cause skin inflammation and how this affects antibiotic concentration in inflamed and healthy tissues. This research may help improve treatment strategies for skin infections.

Skin Inflammation>2 yearsSafety phase (I)DermatologyInfectious Diseases

Usher Syndrome Type 1B: AAVB-081 Injection Study

We are testing a new subretinal injection for patients with Usher Syndrome Type 1B to see if it is safe and how it affects retinal health. The goal is to find a dose that balances safety and effectiveness.

Usher Syndrome Type 1B>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Immune Thrombocytopenia: Pirtobrutinib Study

We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.

Immune Thrombocytopenia≤3 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteHematology

Echinococcosis: Albendazole Study

We are examining how the medication Albendazole is processed in the body of patients with cystic and alveolar echinococcosis. This study aims to improve treatment strategies for these infections.

Human Echinococcosis>2 yearsSafety phase (I)Infectious Diseases

Healthy Adults: Effect of High-Fat Meal on DO-2

We are studying how a high-fat meal influences the way the medication DO-2 is absorbed in healthy individuals. This research may help us understand the best way to use this treatment.

Healthy Volunteers6-12 monthsSafety phase (I)Internal Medicine

NTS-521: Safety Study in Adults and Elderly

We are investigating how safe different doses of NTS-521 are for adults and elderly individuals. The study looks at how the body reacts to the drug and how the drug is processed over time.

Healthy ParticipantsSafety phase (I)Internal MedicineNeurology

Critical Limb Ischemia: L-PRF Treatment Study

We are investigating the safety of a new treatment using patient-derived fibrin for individuals with critical limb ischemia. The study also looks at its potential effects on limb health and quality of life.

Critical Limb Ischemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Acute Inflammation Response: Lipopolysaccharides Study

We are testing how healthy volunteers respond to a substance that triggers inflammation. This research may help improve understanding of inflammatory diseases.

Healthy VolunteersSafety phase (I)Infectious DiseasesInternal Medicine

Patritumab Deruxtecan for Pediatric Solid Tumors

We are studying a new treatment for children with relapsed or refractory solid tumors to see if it is safe and effective. This trial aims to understand how well it works compared to existing options.

HepatoblastomaRhabdomyosarcoma>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesCost ReimbursementOncologyPediatrics

Refractory B Cell Autoimmune Diseases: CNTY-101 Treatment

We are testing CNTY-101, a new cell therapy, for people with hard-to-treat B cell autoimmune diseases. The goal is to see if it can improve their condition compared to standard treatments.

Systemic Lupus Erythematosus and Related Conditions>2 yearsSafety phase (I)DermatologyInfectious DiseasesRheumatology

Durvalumab for Non-Surgical Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of the immunotherapy durvalumab followed by radiation in patients with early stage or locally advanced non-small cell lung cancer. This trial aims to find out if this treatment approach can help those who cannot have surgery.

Non-Small Cell Lung Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology